Having trouble accessing articles? Reset your cache.

Obagi Medical Products Inc., Valeant Pharmaceuticals, Merz deal

Merz withdrew its competing offer to acquire skin disorder company Obagi for $22 per share in cash, which

Read the full 183 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE